Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Turkey / NCT07587853
Starting soon Observational

Genetic Variants in Idiopathic Premature Ovarian Insufficiency

NCT07587853 · tracked via the Priya Life Science Turkey tracker
Sponsor
Abdurrahman Hamdi İnan
Phase
Observational
Started
2026-06-10
Last updated
2026-05-19

Condition(s) studied

Premature Ovarian Insufficiency

Study summary

Premature ovarian insufficiency is a condition in which ovarian function decreases or is lost before the age of 40 years. In many patients, the underlying cause remains unexplained. This prospective observational case-control study aims to investigate pathogenic and likely pathogenic genetic variants in DNA repair and meiotic genes related to ovarian reserve and folliculogenesis in women with idiopathic premature ovarian insufficiency.

The study will include women younger than 40 years with idiopathic premature ovarian insufficiency and age- and ethnicity-matched control participants with normal ovarian function. Clinical and reproductive data will be collected, and a peripheral blood sample will be obtained from each participant for whole exome sequencing. The frequency of pathogenic or likely pathogenic variants will be compared between the case and control groups. No investigational drug, device, or treatment intervention will be administered.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
39 Years
Healthy volunteers
Accepted
Inclusion Criteria: For the idiopathic premature ovarian insufficiency group: * Women aged 18 to 39 years. * Spontaneous amenorrhea or marked menstrual irregularity lasting at least 4 months. * Serum FSH level greater than 25 IU/L. In cases of diagnostic uncertainty, FSH measurement may be repeated after 4 to 6 weeks. * Diagnosis of idiopathic premature ovarian insufficiency, with no known chromosomal abnormality, FMR1 premutation, defined syndromic genetic diagnosis, or iatrogenic cause. * Willingness to participate in the study and ability to provide written informed consent. For the control group: * Women aged 18 to 39 years. * Regular menstrual cycles. * Age-appropriate normal ovarian reserve findings, including FSH and AMH values within age-appropriate reference ranges and, when available, appropriate antral follicle count. * No known history of infertility, premature ovarian insufficiency, or early menopause. * No history of gonadotoxic treatment or ovarian surgery. * Willingness to participate in the study and ability to provide written informed consent. Exclusion Criteria: For both groups: * Known chromosomal abnormality, such as Turner syndrome or structural X chromosome abnormality. * FMR1 premutation carrier status. * Previously defined syndromic genetic diagnosis. * Active malignancy. * History of gonadotoxic chemotherapy or pelvic radiotherapy. * Iatrogenic ovarian damage or iatrogenic premature ovarian insufficiency after ovarian surgery. * Clear autoimmune, endocrine, or other clinical condition that may explain secondary amenorrhea. * Refusal to provide informed consent or request to withdraw study data. * Insufficient DNA sample quality or inability to complete genetic analysis for technical reasons. Additional exclusion criteria for the control group: * Known history of infertility, premature ovarian insufficiency, or early menopause. * Ovarian reserve findings below the expected range for age. * Previous gonadotoxic treatment or ovarian surgery.

Primary outcome measure(s)

  • Prevalence of Pathogenic or Likely Pathogenic Variants in the Target Gene Set — Through study completion, up to 24 months
    Proportion of participants in each group who carry pathogenic or likely pathogenic variants, classified according to ACMG/AMP criteria, in the predefined 57-gene target set related to ovarian reserve, folliculogenesis, DNA repair, and meiosis.

Trial sites (1)

FacilityCityRegionStatus
University of Health Sciences Tepecik Training and Research Hospital, Department of Obstetrics and Gynecology Bornova İzmir
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07587853 on ClinicalTrials.gov ↗ ← All trials in Turkey